Syngene and Biocon are two different entities, and the nature of their work is distinct. As a Contract Research, Development, and Manufacturing Organization (CRDMO), Syngene offers comprehensive, integrated scientific services across the entire drug discovery, development, and manufacturing value chain to its clients. Biocon is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of its own portfolio of biopharmaceutical products.

Established in 1993, Syngene began its journey as a Contract Research Organization (CRO), providing research services to pharma and biotech companies in drug discovery. Today, the company is an integrated Contract Research Development and Manufacturing Organization (CRDMO), providing a comprehensive set of services that span the entire drug lifecycle, supporting clients from early-stage research and discovery all the way through to commercial manufacturing.

With a combined focus on speed, scale, and supply chain security, Syngene offers diversified and qualified sourcing options through a robust supply chain network comprising over 2,900 suppliers across 30 countries. This extensive and well-vetted supplier base ensures reliable access to critical raw materials and components, supporting uninterrupted project execution and reducing supply chain risks for clients.

Syngene is well positioned as a strong partner for biopharmaceutical companies looking to bring new drugs to market faster and more reliably. Its team of over 5,600 scientists functions as an extension of clients’ research teams, pushing the boundaries of scientific discovery.

Syngene’s business divisions include Research Services, Development Services, and Contract Development and Manufacturing Services (CDMO).

Research Services: Syngene’s Research Services division supports the full spectrum of early-stage R&D, from target identification to clinical transition. This integrated division includes Discovery Chemistry, Discovery Biology, Translational & Clinical Research, and Dedicated R&D Centers. Syngene’s expertise spans across small molecules, biologics, and advanced modalities such as peptides, oligonucleotides, antibody-drug conjugates, and targeted protein degradation/stabilization.

Contract Development and Manufacturing Services (CDMO): Syngene’s CDMO services provide comprehensive support across the development, scale-up, and manufacturing lifecycle of drug products. The offering spans from preclinical stages through clinical trials to commercial supply. Services are available as integrated solutions or as stand-alone offerings and include drug substance and drug product development, process and analytical development, formulation, scale-up, Good Manufacturing Practices (GMP)-compliant manufacturing, packaging, and distribution.

• Small molecule CDMO: Small molecule CDMO capabilities begin with Syngene’s Development Services division, which advances promising candidates originating primarily from Research Services. The division focuses on small molecule drug substance and drug product development, ensuring safety, tolerability, and efficacy. Syngene also supports next-generation modalities such as antibody-drug conjugates (ADCs), oligonucleotides, and peptides, enabling a seamless, science-driven transition to GMP -compliant manufacturing. Development is supported by integrated analytical services for method development, validation, transfer, and reference standard qualification.

Manufacturing for small molecules is conducted at the US FDA-compliant API facility in Mangaluru, ensuring high-quality and regulatory-compliant production.

• Large molecule CDMO: Large molecule development and manufacturing covers the spectrum of human and animal health and is conducted at the biologics facilities in Bengaluru, approved by US and European regulatory authorities. The company has also acquired a state-of-the-art manufacturing facility in the United States. Once operational, the facility will expand Syngene’s ability to serve customers across regions with greater flexibility and scale.

India

Bengaluru (Headquarters):
This is Syngene’s central hub for integrated research, development, and manufacturing. The Bengaluru campuses span over 2.5 million sq. ft. of infrastructure and include:

• Discovery Chemistry, Discovery Biology, Translational and Clinical Research laboratories
• Dedicated R&D Centers
• Large molecule biologics development and manufacturing facilities, approved by the US FDA and European regulatory authorities
• Fill-finish capabilities and commercial-scale drug substance manufacturing

Hyderabad:

An expanding campus led by the growing demand for research services, particularly in emerging areas such as antibody-drug conjugates (ADCs), peptides, and oligonucleotides. The site also contributes to Discovery Biology, Drug Metabolism and Pharmacokinetics (DMPK), and Compound Management services.

Mangaluru:
This site hosts Syngene’s API (Active Pharmaceutical Ingredient) manufacturing facility, which is dedicated to small molecule development and manufacturing. It supports clinical and commercial-scale production, aligned with global regulatory standards.

United States

Syngene expanded its global footprint by acquiring a state-of-the-art biologics manufacturing facility in Baltimore, Maryland. The facility increases Syngene’s total single-use bioreactor capacity to 50,000L, supporting monoclonal antibody and recombinant protein manufacturing for both clinical and commercial supply.

Syngene’s research covers a broad range of therapeutic areas, including oncology, immunology, inflammation, metabolic disorders (such as diabetes), cardiovascular diseases, infectious diseases, fibrosis, and neurological conditions. These areas reflect the company’s focus on addressing some of the most pressing global health challenges through science-led innovation.

To support these therapeutic areas, Syngene provides a comprehensive suite of services that span the entire drug development lifecycle: from early-stage research and target identification to advancing drug candidates through clinical trials and enabling commercial-scale production. The company’s integrated approach ensures safety, efficacy, and scalability across small and large molecule projects.

Syngene also incorporates cutting-edge technologies into its service offerings, including CAR-T cells, mRNA, antibody-drug conjugates (ADCs), oligonucleotides, and bispecific antibodies. Notably, it has built one of the world’s largest Proteolysis Targeting Chimera (PROTAC) teams, with over 500 scientists working on novel approaches to treat cancer through targeted protein degradation.

Syngene recognises the potential of automation and digitization to drive scientific excellence. The company continuously invests in integrating the latest technologies across its research and manufacturing value chain. Some examples include:

• The company has implemented cloud-based Electronic Lab Notebooks (ELNs) for Discovery Services to automate workflows, reduce manual errors, and improve data traceability.
• In compound management, Syngene operates a centralized, automated hub that integrates automated liquid-handling systems and artificial intelligence (AI)-powered software, significantly improving screening speed, inventory accuracy, and standardization.
• On the manufacturing side, Syngene has deployed Electronic Batch Manufacturing Records (eBMRs) in Biologics and Chemical Development to enhance data integrity and regulatory compliance. The implementation of Laboratory Information Management Systems (LIMS), predictive maintenance tools, and Information Technology–Operational Technology (IT-OT) integration contributes to better planning, monitoring, and production efficiency.
• At an enterprise level, Project VEGA integrates core systems such as SAP and Salesforce to automate business processes including demand forecasting, proposal generation, and contract lifecycle management. This reduces manual effort, enhances decision-making, and strengthens customer engagement.

To drive continuous improvement, Syngene complements its digital initiatives with Lean Six Sigma practices, kaizen programs, and real-time performance dashboards. These efforts support measurable gains in productivity, quality, and scientific excellence across the organization.

Syngene sees Artificial Intelligence (AI) and Machine Learning (ML) as important enablers in its efforts to enhance scientific productivity and operational efficiency. These technologies are being systematically integrated into both research and enterprise operations to support informed decision-making and improve turnaround times.

In Research Services, Syngene has continued to strengthen its AI-driven platforms. The proprietary Syn.AI™ platform supports data-led drug discovery by helping researchers evaluate and prioritize targets based on attributes such as disease relevance and druggability. This contributes to more informed and efficient early-stage discovery.

In parallel, the SARchitect™ platform is being enhanced to support Quantitative Structure-Activity Relationship (QSAR) modelling. This platform helps scientists understand how the structure of a chemical affects its biological activity, making it easier and faster to design and improve new molecules.

These platforms are integrated into Syngene’s scientific workflows to complement traditional discovery approaches with predictive modelling, thereby enabling better resource allocation and reducing time spent on non-viable targets.

Beyond R&D, Syngene is investing in scalable digital solutions and piloting AI-enabled tools across various functions to enhance operational excellence. For instance, the company is leveraging AI to automate demand forecasting, improve proposal turnaround time, and streamline contract lifecycle management as part of its enterprise digital transformation program, Project VEGA. These initiatives are helping reduce manual effort, improve decision-making, and deliver greater responsiveness to client needs.

Overall, Syngene’s approach to AI and ML is focused on building practical, scalable capabilities that deliver value to clients and strengthen internal efficiencies across the drug development lifecycle.

Syngene offers diverse career opportunities across the life sciences spectrum, encompassing discovery research, development services, and commercial-scale manufacturing. With over 8,200 employees, including more than 5,600 scientists, the organization provides a professional environment that supports scientific advancement and cross-functional collaboration. It offers a dynamic and purpose-driven environment for professionals to work at the cutting edge of science without the need to relocate from India.

Opportunities are available in scientific, technical, and corporate functions, including research, process development, quality, manufacturing, engineering, regulatory affairs, and enabling services such as IT, HR, finance, and project management. As the company expands its focus on digital transformation and AI-driven platforms, it is also building capabilities in areas like data science and bioinformatics.

Syngene emphasizes continuous learning and talent development through structured programs tailored to various career stages. The Syngene Management & Leadership Academy and My Future Plan initiative help employees navigate career growth, while partnerships with academic institutions and digital platforms support ongoing skill development.

Employee well-being is supported through the Thrive360 framework, which addresses physical, emotional, social, financial, and professional wellness. The company also prioritizes inclusion and diversity and has been recognised among the top pharmaceutical companies in India for women employees by Fortune India.

Syngene places a strong emphasis on diversity, equity, and inclusion (DEI), and aims to foster a workforce that brings a wide array of perspectives, skills, and experiences to enhance innovation and improve decision-making. The company continuously evaluates its core processes to ensure gender neutrality. Currently, women comprise 28% of the workforce, significantly higher than the industry average of 11% in India (Source: Mercer Study, 2022).

Reflecting its ongoing commitment to DEI, Syngene was ranked the #1 pharmaceutical company for women employees in Fortune India’s Top 10 list for 2024, underscoring its efforts to build an inclusive and empowering workplace.

Syngene has embedded Environmental, Social, and Governance (ESG) principles across its operations, aligning its growth with long-term sustainability goals. Its ESG framework focuses on environmental stewardship, social responsibility, and strong governance, with clearly defined targets and accountability mechanisms.

Environmental: Syngene’s environmental strategy is guided by its commitment to the Science Based Targets initiative (SBTi). The company aims to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 50% by 2033 and has committed to engaging suppliers responsible for over 81% of Scope 3 emissions to adopt aligned reduction targets. In FY25, 92% of Syngene’s total energy consumption came from renewable sources, with the BSEZ campus achieving 96%. The company also recycled or co-processed 95.47% of its hazardous and non-hazardous waste and implemented energy conservation projects saving 17.82 lakh kWh of electricity.

Water conservation remains a critical focus, with 64% of water used sourced from reused, recycled, or harvested sources. Rainwater harvesting, water audits, and the use of recycled water across functions like cooling towers and restrooms are central to Syngene’s strategy to reduce freshwater dependency.

Social: Community initiatives span across education, health, environmental sustainability, and urban infrastructure, with active employee volunteering across cities. Flagship programs include STEM (Science, Technology, Engineering, and Mathematics) scholarships for women from tier-2 and tier-3 institutions, and the annual Synquizitive science quiz reaching thousands of students in government schools.

Governance: Syngene’s ESG governance structure is aligned with international standards, including the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB). The company is a signatory to the United Nations Global Compact and a Supplier Partner with the Pharmaceutical Supply Chain Initiative (PSCI), reinforcing its commitment to responsible sourcing and ethical business conduct.

Syngene also received several external recognitions in FY25:

• EcoVadis Silver rating u to
• MSCI ESG rating improved to ‘A’
• CDP score of ‘B’ for both climate change and water security
• Ranked 91st in Business World’s India’s Most Sustainable Companies, and 9th in the pharmaceutical category
• Named one of the ‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista